Targeting Oncoimmune Drivers of Cancer Metastasis
Open Access
- 1 February 2021
- Vol. 13 (3), 554
- https://doi.org/10.3390/cancers13030554
Abstract
Residual metastasis is a major cause of cancer-associated death. Recent advances in understanding the molecular basis of the epithelial–mesenchymal transition (EMT) and the related cancer stem cells (CSCs) have revealed the landscapes of cancer metastasis and are promising contributions to clinical treatments. However, this rarely leads to practical advances in the management of cancer in clinical settings, and thus cancer metastasis is still a threat to patients. The reason for this may be the heterogeneity and complexity caused by the evolutional transformation of tumor cells through interactions with the host environment, which is composed of numerous components, including stromal cells, vascular cells, and immune cells. The reciprocal evolution further raises the possibility of successful tumor escape, resulting in a fatal prognosis for patients. To disrupt the vicious spiral of tumor–immunity aggravation, it is important to understand the entire metastatic process and the practical implementations. Here, we provide an overview of the molecular and cellular links between tumors’ biological properties and host immunity, mainly focusing on EMT and CSCs, and we also highlight therapeutic agents targeting the oncoimmune determinants driving cancer metastasis toward better practical use in the treatment of cancer patients.This publication has 191 references indexed in Scilit:
- Follistatin-Like 1: A Potential Mediator of Inflammation in ObesityMediators of Inflammation, 2013
- COX-2 in cancer: Gordian knot or Achilles heel?Frontiers in Pharmacology, 2013
- A CXCL1 Paracrine Network Links Cancer Chemoresistance and MetastasisCell, 2012
- Functional Interactions between Retinoblastoma and c-MYC in a Mouse Model of Hepatocellular CarcinomaPLOS ONE, 2011
- Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell ResponsesThe Journal of Immunology, 2011
- Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritisArthritis Research & Therapy, 2011
- Aurora B Interacts with NIR-p53, Leading to p53 Phosphorylation in Its DNA-binding Domain and Subsequent Functional SuppressionOnline Journal of Public Health Informatics, 2011
- Follistatin‐like protein 1 is a mesenchyme‐derived inflammatory protein and may represent a biomarker for systemic‐onset juvenile rheumatoid arthritisArthritis & Rheumatism, 2010
- Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factorsNature Reviews Cancer, 2010
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2009